...
首页> 外文期刊>World Journal of Gastroenterology >Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.
【24h】

Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.

机译:他莫昔芬可以在体内逆转大肠癌的多药耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To investigate the effect of tamoxifen (TAM) on multidrug resistance (MDR) of colorectal carcinoma in vivo and its relationship with estrogen receptor (ER). METHODS: Multidrug resistance was determined by means of semi-quantitative retro-transcription polymerase chain reaction (RT-PCR) to test mdr1 gene mRNA and ER expression was studied by immunohistochemistry. Tumor tissues from three cases of human colon carcinoma, which had mdr1(+)/ER(+), mdr1(+)/ER(-), mdr1(-) expressions, were planted subcutaneously in the neck of nude mice to establish three xenograft models. These models were subdivided into four subgroups randomly: Doxorubicin (DOX)-treated group, TAM-treated group, DOX and TAM group and control group. The dimensions of these xenografts were measured after each course of treatment and the xenografts were removed at the end of the experiments for measurements of weight and the variation of mdr1 mRNA level with RT-PCR. In each course, TAM (15 mg/(kg/d)) was administrated orally per day in the first seven days and DOX (3.6 mg/kg) was injected peritoneally on the first day. Data was evaluated by q and t tests. RESULTS: In the animal models with mdr1(-) tumor, the weights and volumes of the planted tumor in DOX group ((39.1+/-2.29) mg, (31.44+/-1.61) mm(3)) and TAM and DOX group ((38.72+/-2.56) mg, (31.31+/-1.74) mm(3)), which were lesser than that of control group ((45.48+/-3.92) mg, (36.42+/-2.77)mm(3), P = 0.037, P = 0.016 respectively) significantly. In the animal models with mdr1(+)/ER(+) tumor, the weights and volumes of planted tumor were not affected by DOX or TAM treatment; however, in TAM and DOX group ((425.5+/-28.58) mg, (340.35+/-22.28) mm(3)), they were significantly less than that of control group ((634.23+/-119.41) mg, (507.45+/-93.34) mm(3), P = 0.022, P = 0.045 respectively), which are similar to that in the models with mdr1(+)/ER(-) tumor. No significant changes were found in the expressive level of mdr1 mRNA following these treatments. CONCLUSION: The expression of mdr1 gene corresponds to the sensitivity of colon cancer to anti-tumor drugs in vivo. TAM can reverse the MDR of colorectal carcinoma in nude mice, which is independent of the expression of ER; however, no change was observed in the expressive level of mdr1 mRNA.
机译:目的:探讨他莫昔芬(TAM)对大肠癌体内多药耐药(MDR)的影响及其与雌激素受体(ER)的关系。方法:采用半定量逆转录聚合酶链反应(RT-PCR)法检测mdr1基因的mRNA表达,并通过免疫组化研究ER的表达。将三种具有mdr1(+)/ ER(+),mdr1(+)/ ER(-),mdr1(-)表达的人类结肠癌病例的肿瘤组织皮下植入裸鼠的颈部,以建立三个异种移植模型。这些模型随机分为四个亚组:阿霉素(DOX)治疗组,TAM治疗组,DOX和TAM组以及对照组。在每个疗程后测量这些异种移植物的尺寸,并在实验结束时去除异种移植物,以通过RT-PCR测量重量和mdr1 mRNA水平的变化。在每个疗程中,在前7天每天口服TAM(15 mg /(kg / d)),并在第一天腹膜注射DOX(3.6 mg / kg)。通过q和t检验评估数据。结果:在具有mdr1(-)肿瘤的动物模型中,DOX组((39.1 +/- 2.29)mg,(31.44 +/- 1.61)mm(3))以及TAM和DOX的种植瘤的重量和体积组((38.72 +/- 2.56)mg,(31.31 +/- 1.74)mm(3)),小于对照组((45.48 +/- 3.92)mg,(36.42 +/- 2.77)mm (3),P = 0.037,P = 0.016)显着。在具有mdr1(+)/ ER(+)肿瘤的动物模型中,植入的肿瘤的重量和体积不受DOX或TAM处理的影响;但是,在TAM和DOX组中((425.5 +/- 28.58)mg,(340.35 +/- 22.28)mm(3)),它们显着小于对照组((634.23 +/- 119.41)mg,( 507.45 +/- 93.34)mm(3),分别为P = 0.022,P = 0.045),与具有mdr1(+)/ ER(-)肿瘤的模型相似。在这些处理后,没有发现mdr1 mRNA表达水平的显着变化。结论:mdr1基因的表达与结肠癌对体内抗肿瘤药物的敏感性有关。 TAM可以逆转裸鼠大肠癌的MDR,而与ER的表达无关。但是,没有观察到mdr1 mRNA表达水平的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号